Overview

Bioequivalence Study of Patches With Different Equilibration Profiles

Status:
Completed
Trial end date:
2004-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this single center, randomized, double-blind, 2 way crossover study was to determine the bioequivalence of a norelgestromin/ethinyl estradiol (NGMN/EE) transdermal contraceptive system.
Phase:
Phase 1
Details
Lead Sponsor:
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Treatments:
Contraceptive Agents
Estradiol
Estradiol 17 beta-cypionate
Estradiol 3-benzoate
Estradiol valerate
Ethinyl Estradiol
Norelgestromin
Norgestrel
Ortho Evra
Polyestradiol phosphate